Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease
Il-Kang Na, … , Nicole Beauchemin, Marcel R.M. van den Brink
Il-Kang Na, … , Nicole Beauchemin, Marcel R.M. van den Brink
Published January 4, 2010; First published December 1, 2009
Citation Information: J Clin Invest. 2010;120(1):343-356. https://doi.org/10.1172/JCI39395.
View: Text | PDF
Categories: Research Article Transplantation

The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease

  • Text
  • PDF
Abstract

Thymic graft-versus-host disease (tGVHD) can contribute to profound T cell deficiency and repertoire restriction after allogeneic BM transplantation (allo-BMT). However, the cellular mechanisms of tGVHD and interactions between donor alloreactive T cells and thymic tissues remain poorly defined. Using clinically relevant murine allo-BMT models, we show here that even minimal numbers of donor alloreactive T cells, which caused mild nonlethal systemic graft-versus-host disease, were sufficient to damage the thymus, delay T lineage reconstitution, and compromise donor peripheral T cell function. Furthermore, to mediate tGVHD, donor alloreactive T cells required trafficking molecules, including CCR9, L selectin, P selectin glycoprotein ligand-1, the integrin subunits αE and β7, CCR2, and CXCR3, and costimulatory/inhibitory molecules, including Ox40 and carcinoembryonic antigen-associated cell adhesion molecule 1. We found that radiation in BMT conditioning regimens upregulated expression of the death receptors Fas and death receptor 5 (DR5) on thymic stromal cells (especially epithelium), while decreasing expression of the antiapoptotic regulator cellular caspase-8–like inhibitory protein. Donor alloreactive T cells used the cognate proteins FasL and TNF-related apoptosis-inducing ligand (TRAIL) (but not TNF or perforin) to mediate tGVHD, thereby damaging thymic stromal cells, cytoarchitecture, and function. Strategies that interfere with Fas/FasL and TRAIL/DR5 interactions may therefore represent a means to attenuate tGVHD and improve T cell reconstitution in allo-BMT recipients.

Authors

Il-Kang Na, Sydney X. Lu, Nury L. Yim, Gabrielle L. Goldberg, Jennifer Tsai, Uttam Rao, Odette M. Smith, Christopher G. King, David Suh, Daniel Hirschhorn-Cymerman, Lia Palomba, Olaf Penack, Amanda M. Holland, Robert R. Jenq, Arnab Ghosh, Hien Tran, Taha Merghoub, Chen Liu, Gregory D. Sempowski, Melissa Ventevogel, Nicole Beauchemin, Marcel R.M. van den Brink

×

Figure 3

Alloreactive T cells require FasL and TRAIL to mediate tGVHD.

Options: View larger image (or click on image) Download as PowerPoint
Alloreactive T cells require FasL and TRAIL to mediate tGVHD.
(A) BM-der...
(A) BM-derived CD4+CD8+ (DP) thymocytes in recipients of B6 CD45.1 TCD-BM with or without 0.25 × 106 B6 versus B6.KO (deficient for cytolytic molecules) donor T cells on day 28. BM only, n = 18; WT T cells, n = 21; gld (FasL deficient), n = 8; Trail–/–, n = 8; gld/Trail–/–, n = 7; gld/Trail–/–Tnf–/–, n = 6; Pfp–/–, n = 12; Tnf–/–, n = 12; Ifng–/–, n = 16; combined data from 2 independent experiments. (B) Experiment as in A with 0.5 × 106 donor T cells. BM only, n = 22; WT T cells, n = 20; gld, n = 13; Trail–/–, n = 13; gld/Trail–/–Tnf–/–, n = 13; Pfp–/–, n = 12; Ifng–/–, n = 9; combined data from 2 to 3 independent experiments. (A and B) *P < 0.05, **P < 0.01 versus WT. (C) Thymic architecture of thymus sections from A were analyzed (H&E, day 28). Representative sections are shown. Original magnification, ×50. n = 5/group. (D) Total thymocyte counts in mice that received B6 BM with or without 0.25 × 106 CD5+ B6 WT CD4, WT CD8, Trail–/– CD4, Trail–/– CD8, gld CD4, or gld CD8 T cells. Symbols represent individual animals (mean ± SEM). *P < 0.05. n = 6–7/group. (E) Absolute numbers of BM-derived CD45.1+CD4+CD8+ thymocytes in lpr (Fas receptor deficient) and WT B6 recipients on day 28. Symbols represent individual animals (mean ± SEM). n = 8/group. **P < 0.01 versus corresponding WT controls. (F) Total thymocytes in recipients of lpr or WT B6 TCD-BM and T cells on day 28. Dots represent individual animals. Horizontal bars indicate the mean (A, B, and F). n = 8–10/group.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts